p-tau217 – Medxy AI

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

By MedXY 04/07/2026

This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cognitive decline.

Clinical Updates Neurology news

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

By MedXY 03/10/2026

This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.

Neurology news

Sex-Specific P-Tau217 Dynamics: Why Women Exhibit Accelerated Tau Accumulation and Cognitive Decline

By MedXY 02/20/2026

A multi-cohort study demonstrates that women with amyloid-β pathology show higher plasma p-tau217 levels and faster tau PET accumulation than men, providing a biological basis for their increased risk of rapid cognitive decline in preclinical Alzheimer’s disease.

Neurology news

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

By MedXY 02/06/2026

Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiveness in detecting amyloid-β pathology.

Clinical Updates Neurology news Pathology & Lab Medicine

Precision Screening for Preclinical Alzheimer Disease: The Ascendance of Plasma p-tau217 as a Scalable Biomarker

By MedXY 01/02/2026

This review synthesizes recent high-impact evidence on plasma p-tau217, demonstrating its superior utility in identifying amyloid pathology, predicting cognitive decline, and optimizing recruitment for primary prevention trials in cognitively unimpaired individuals.

Neurology news

Plasma p-tau217 and GFAP Emerge as Robust Predictors of Alzheimer’s Progression in Down Syndrome

By MedXY 12/23/2025

A pivotal longitudinal study demonstrates that plasma p-tau217 and GFAP accurately predict amyloid-β and tau deposition, cognitive decline, and dementia risk in adults with Down syndrome, offering a transformative, non-invasive tool for clinical monitoring and therapeutic trials.

Cardiology Neurology news Specialties

Obicetrapib’s Role in Modulating Alzheimer’s Disease Biomarkers in Patients with Cardiovascular Disease: A Landmark Clinical Study

By MedXY 10/21/2025

Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.

Neurology news

Pregnancy Hypertension and Elevated p-tau217: A Midlife Indicator of Alzheimer’s Disease Risk in Women

By MedXY 10/21/2025

Pregnancy hypertension is independently associated with higher serum p-tau217 levels in midlife women, suggesting a link to preclinical Alzheimer’s disease pathology and potential for early screening and intervention.